Beck Bode LLC’s Axsome Therapeutics AXSM Stock Holding History

Beck Bode LLC’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-102,127	Closed	-$3.37M	–	88
2021 Q3	$3.37M	Buy	+102,127	New	+$3.98M	0.94%	35

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beck Bode LLC's AXSM Position: Q4 2021 in Review

Beck Bode LLC sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 102,127 shares — an estimated $3.37M sold.

Beck Bode LLC first reported a position in AXSM in Q3 2021 and held it in 1 quarter. The position peaked at $3.37M in Q3 2021. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

Beck Bode LLC reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
Beck Bode LLC sold 102,127 Axsome Therapeutics shares in Q4 2021, an estimated $3.37M.
Beck Bode LLC first reported a position in Axsome Therapeutics in Q3 2021 and held it in 1 quarter.
Beck Bode LLC's Axsome Therapeutics position peaked at $3.37M in Q3 2021.
167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on Beck Bode LLC's 13F filing for Q4 2021, filed 7 Feb 2022.